Efti in MBC - phase 3 = $20 million and 2-4 years. If Frederick can find reasonable grounds in sub-groups then its possible for a phase 3 trial to be funded, but not by Immutep (imo). Big Pharma may have a crack - MBC is difficult to treat and remains a high unmet need. Possible licensing deal - $upfront to cover our P1-2b costs and milestone/royalties.
TACTI-002 is where the rub is - thus far Keytruda mono has a 20% response rate in NSCLC (80% of all lung cancer) The FDA’s initial approval of Keytruda (pembrolizumab)immunotherapy was based in part on data from the KEYNOTE-001 clinical trial,which initially showed that Keytruda alone had an overall response rate ofnearly 20% among previously treated and treatment-naive patients with advancedNSCLC whose cancers expressed high levels of PD-L1.Noting FDA approval for Keytruda in this setting is only for high PD-1 expression.
Keytruda and Efti in NSCLC - 47% overall response rate. Admittedly small cohort BUT this is for allcomer PD-1 status....Patients byPD-L1 categoryNo. of ResponsesiORRLow (< 1%)133%Medium (1-49%)350%High (≥ 50%)375%Not evaluable125%Overall847%
Patients by
PD-L1 category
No. of Responses
iORR
1 Low (< 1%)
1
33%
2 Medium (1-49%)
3
50%
3 High (≥ 50%)
3
75%
4 Not evaluable
1
25%
5 Overall
8
47%
- Forums
- ASX - By Stock
- IMM
- CYTLIMIC positive results - YNP01 Phase 1 trial
CYTLIMIC positive results - YNP01 Phase 1 trial, page-6
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M |
Open | High | Low | Value | Volume |
37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 48648 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 13814 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 48648 | 0.365 |
7 | 164694 | 0.360 |
4 | 31498 | 0.355 |
7 | 161310 | 0.350 |
3 | 12221 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 13814 | 2 |
0.375 | 175836 | 7 |
0.380 | 137322 | 5 |
0.385 | 53062 | 4 |
0.390 | 197301 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online